ORKA
Oruka Therapeutics IncHenter pris…
Værdiansættelse (TTM)
Kursudvikling
Kun 82 handelsdage i databasen. Viser al tilgængelig historik.
Data-readiness
10 års prishistorik er idealet for høj confidence.
- Prishistorik
- 0,2 år
- Pris-dage
- 58
- Årsregnskaber
- 23
- Peers
- 0/0
- Valuation
- 1/6
- Fundamentals
- 6/8
- Datovindue
- 2026-02-17 til 2026-05-08
Blokkere
- Raw confidence is below the 0.95 high-confidence guardrail.
Mangler før højere confidence
- Mangler ca. 9,8 års prishistorik før ideal/full.
- Backfill mindst 1 års daglige priser før seriøs teknisk vurdering.
- Kør compute-multiples for manglende valuation metrics.
- Kør fetch-fundamentals-bulk/API fallback for manglende regnskabsmetrics.
Seneste assessment
ORKA vurderet 2026-06-10
Raw confidence is below the 0.95 high-confidence guardrail.
Stores exit-aware fields without issuing sell scores yet.
Current drawdown: Future exit logic can use drawdown from recent high.
Trend break: Future exit logic can use moving-average trend breaks.
Compares price paid with earnings, cash-generation proxies and sales.
P/E: Reasonable P/E gets rewarded; very expensive or distressed multiples do not.
Earnings yield: Earnings yield is the inverse P/E lens.
Checks trend, momentum and current damage from recent highs.
6M momentum: Positive medium-term momentum confirms sponsorship.
Trend stack: Strong setup keeps price above MA50 and MA200 with MA50 above MA200.
Checks whether the assessment has enough recent price, fundamental and valuation data.
Price history depth: More than one trading year gives the technical pillar enough context.
Latest price freshness: Latest live or EOD price should be recent.
Treats macro as context, not a standalone trading instruction.
VIX: Normal volatility is supportive; panic or complacency is less clean.
10Y-2Y curve: Positive yield curve lowers recession stress.
Scores growth, margins, capital efficiency, balance-sheet resilience and composite financial-health KPIs.
Revenue growth 3Y: Sustained top-line growth supports durable compounding.
Gross margin: High gross margin gives room for reinvestment and downturns.
Adds relative context when sector peers have comparable data.
Peer count: Peer context is only scored when comparable data exists.
P/E vs peers: P/E relative valuation needs both own multiple and peer median.
Insider activity
| Dato | Person | Rolle | Type | Antal | Værdi | Kilde |
|---|---|---|---|---|---|---|
| 22.6.2026 | Agarwal Arjun | Senior Vice President, Finance | ▼ SALG | -888 | -71.049 USD | sec |
| 15.6.2026 | Quinlan Paul T | General Counsel | ▼ SALG | -733 | -51.083 USD | sec |
| 15.6.2026 | Sandler Laura Lee | Chief Operating Officer | ▼ SALG | -600 | -41.814 USD | sec |
| 15.6.2026 | Klein Lawrence Otto | Chief Executive Officer | ▼ SALG | -1.729 | -120.494 USD | sec |
| 15.6.2026 | Goncalves Joana | Chief Medical Officer | ◆ OPT. | 3.500 | 23.940 USD | sec |
| 15.6.2026 | Goncalves Joana | Chief Medical Officer | ▼ SALG | -1.636 | -111.876 USD | sec |
| 15.6.2026 | Agarwal Arjun | Senior Vice President, Finance | ▼ SALG | -395 | -27.528 USD | sec |
| 12.6.2026 | Agarwal Arjun | Senior Vice President, Finance | ◆ OPT. | 8.000 | 100.000 USD | sec |
| 12.6.2026 | Dambkowski Carl | — | ▼ SALG | -12.583 | -882.182 USD | sec |
| 12.6.2026 | Agarwal Arjun | Senior Vice President, Finance | ▼ SALG | -1.859 | -127.048 USD | sec |
| 11.6.2026 | Dambkowski Carl | — | ▼ SALG | -22.417 | -1.572.201 USD | sec |
| 21.5.2026 | Dambkowski Carl | — | ◆ OPT. | 38.689 | 264.633 USD | sec |
| 21.5.2026 | Dambkowski Carl | — | ▼ SALG | -38.318 | -2.238.794 USD | sec |
| 18.5.2026 | Agarwal Arjun | Senior Vice President, Finance | ◆ OPT. | 2.000 | 25.000 USD | sec |
| 18.5.2026 | Agarwal Arjun | Senior Vice President, Finance | ▼ SALG | -4.190 | -244.465 USD | sec |
| 15.5.2026 | Goncalves Joana | Chief Medical Officer | ▼ SALG | -4.800 | -295.495 USD | sec |
| 15.5.2026 | Goncalves Joana | Chief Medical Officer | ◆ OPT. | 3.500 | 23.940 USD | sec |
Earnings
| Quarter | Date | EPS actual | EPS est | EPS surprise | Revenue surprise | |
|---|---|---|---|---|---|---|
| 2026Q1 | 30.4.2026 | -0,48 | -0,54 | +11.6% | +11.6% | Beat |
| 2025Q4 | 30.1.2026 | -0,45 | -0,62 | +26.9% | +26.9% | Beat |
| 2025Q3 | 30.10.2025 | -0,55 | -0,52 | -5.0% | -5.0% | Inline |
| 2025Q2 | 30.7.2025 | -0,46 | -0,43 | -6.4% | -6.4% | Miss |